Lymphoblastic Lymphoma Clinical Trials

62 recruitingLast updated: July 17, 2026

There are 62 actively recruiting lymphoblastic lymphoma clinical trials across 33 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, Philadelphia, Pennsylvania, United States, Seattle, Washington, United States. Updated daily from ClinicalTrials.gov.


Lymphoblastic Lymphoma Trials at a Glance

62 actively recruiting trials for lymphoblastic lymphoma are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Phase 2 with 30 trials, with the heaviest enrollment activity in Houston, Philadelphia, and Seattle. Lead sponsors running lymphoblastic lymphoma studies include M.D. Anderson Cancer Center, Children's Oncology Group, and Baylor College of Medicine.

Browse lymphoblastic lymphoma trials by phase

Treatments under study

About Lymphoblastic Lymphoma Clinical Trials

Looking for clinical trials for Lymphoblastic Lymphoma? There are currently 24 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lymphoblastic Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lymphoblastic Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 62 trials

Recruiting
Phase 3

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Mixed Phenotype Acute LeukemiaB Acute Lymphoblastic LeukemiaB Lymphoblastic Lymphoma+2 more
Children's Oncology Group5,951 enrolled231 locationsNCT03959085
Recruiting
Phase 2

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
St. Jude Children's Research Hospital128 enrolled3 locationsNCT06533748
Recruiting
Phase 1Phase 2

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Acute Lymphoblastic LeukemiaSmall Lymphocytic LymphomaLymphoblastic Lymphoma+4 more
National Cancer Institute (NCI)132 enrolled1 locationNCT06364423
Recruiting
Phase 1

First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

Lymphoblastic LymphomaAcute Lymphoblastic Leukemia ALL
Allterum Therapeutics, Inc24 enrolled4 locationsNCT07586618
Recruiting
Phase 2

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

T-lymphoblastic LymphomaT Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center160 enrolled1 locationNCT00501826
Recruiting
Phase 4

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Acute Lymphoblastic LeukemiaMixed Phenotype Acute LeukemiaLymphoblastic Lymphoma
St. Jude Children's Research Hospital850 enrolled5 locationsNCT06289673
Recruiting
Not Applicable

Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia

Acute Lymphoblastic LeukemiaT-Cell Lymphoblastic Lymphoma
University of Chicago48 enrolled1 locationNCT06446661
Recruiting
Phase 1

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

Hematopoietic and Lymphatic System NeoplasmAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+9 more
City of Hope Medical Center46 enrolled3 locationsNCT07020533
Recruiting
Not Applicable

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+5 more
Children's Hospital of Philadelphia50 enrolled1 locationNCT03810196
Recruiting
Not Applicable

Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia

Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
Northwestern University60 enrolled1 locationNCT03932903
Recruiting
Phase 2

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic Leukemia+25 more
Masonic Cancer Center, University of Minnesota300 enrolled1 locationNCT03314974
Recruiting
Phase 1Phase 2

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

Acute Myeloid LeukemiaNK-Cell LymphomaT-cell Acute Lymphoblastic Leukemia+1 more
Shenzhen Geno-Immune Medical Institute30 enrolled1 locationNCT04033302
Recruiting
Phase 1

Universal 4SCAR7U Targeting CD7-positive Malignancies

Acute Myeloid LeukemiaNK-Cell LymphomaT-cell Acute Lymphoblastic Leukemia+1 more
Shenzhen Geno-Immune Medical Institute30 enrolled1 locationNCT05995028
Recruiting
Phase 2

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic LeukemiaRecurrent B Lymphoblastic Lymphoma+1 more
Children's Oncology Group80 enrolled157 locationsNCT02981628
Recruiting

CAYA Cancer Prospective Cohort Study

CancerPediatric CancerAcute Lymphoblastic Leukemia ALL+1 more
Resonance, Inc.6,000 enrolled3 locationsNCT07632014
Recruiting
Phase 2

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaHodgkin Lymphoma+16 more
Fred Hutchinson Cancer Center60 enrolled1 locationNCT04195633
Recruiting
Phase 1Phase 2

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

B-cell Acute Lymphoblastic Leukemia (B-ALL)B Lineage Lymphoblastic Lymphoma
Stephan Grupp MD PhD115 enrolled1 locationNCT05480449
Recruiting
Phase 2

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic LeukemiaB Lymphoblastic Lymphoma
M.D. Anderson Cancer Center80 enrolled1 locationNCT02877303
Recruiting

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

OsteosarcomaRecurrent LymphomaLymphoblastic Lymphoma+4 more
Children's Oncology Group420 enrolled79 locationsNCT01790152
Recruiting
Phase 1

Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells

T-cell Acute Lymphoblastic LeukemiaT-cell Acute Lymphoblastic LymphomaT-non-Hodgkin Lymphoma
Baylor College of Medicine27 enrolled2 locationsNCT07220993